BEVERLY, MA and TORONTO, ON--(Marketwired - Sep 9, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the assisted reproductive technologies (ART) and developmental biology research markets, today announced that on September 20 and 21, 2016, in collaboration with Illumina, Inc. and Hamilton Thorne, the Canadian Fertility and Andrology Society (CFAS) is offering an opportunity for ART Lab Professionals to participate in a one-day embryology and hands-on embryo biopsy workshop. CFAS members have the option of attending one of two courses depending on their level of experience and proficiency. Both courses offer a balance between theory and practice.
"We are pleased to support the CFAS as it offers educational programs to advance the science and promote excellence in the field of ART to the benefit of Canadians and children born of this technology," said David Wolf, CEO of Hamilton Thorne.
CFAS President, Heather Shapiro added, "This is the first course of its kind offered in Canada for embryologists and demonstrates a commitment by all three organizations to promote standardization and excellence in the practice of embryology in Canada."
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems that reduce cost, increase productivity, improve results and enable breakthroughs in assisted reproductive technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Novartis, Pfizer, and Dow Chemical.
About the CFAS (www.cfas.ca)
The CFAS is a multidisciplinary national non-profit Society that serves as the voice of reproductive specialists, scientists, and allied health professionals working in the field of Assisted Reproduction in Canada. Celebrating its 62nd year, the mission of the CFAS is to responsibly advance reproductive science and medicine in Canada through leadership, research and guidance. Through its 700 multidisciplinary membership, the CFAS aims to promote excellence in the field of Assisted Reproduction to the benefit of Canadians and children born of this technology.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.